Focus on CMV
Redbiotec develops prophylactic vaccines in the area of CMV (Cytomegalovirus), HPV and Influenza and provides customized solutions in biologics.
News
Prof. Roy awarded gold medal for science
Schlieren, 24 January 2012
Redbiotec and DKFZ extend collaboration
Schlieren, 17 January 2012
The German Cancer Research Institute (DKFZ) and Redbiotec have extended their collaboration in the field of HPV, which started in 2009. Goal of the collaboration is the validation of chimeric VLPs, containing proteins of different serotypes on one VLP.

More children have disabilities due to congenital CMV than genetic disorders (Down syndrome).
Learn more about our proprietary rePAXTM technology.
Find our newest scientific publications here.
Meet us at one of our upcoming events.